NCT03511963View on ClinicalTrials.gov

A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC

PHASE3CompletedINTERVENTIONAL

Enrollment

677

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

April 15, 2020

Study Completion Date

April 20, 2023

Conditions

Metastatic Colorectal Cancer (mCRC)

Interventions

DRUG

HLX04 100 mg in 4 ml Injection

7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)

DRUG

Avastin 100 mg in 4 ml Injection

7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)

Trial Locations (1)

210002

Nanjing Bayi Hospital Ethics Committee, Nanjing

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY

NCT03511963 - A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC | Biotech Hunter | Biotech Hunter